

## Noile-Immune Biotech Welcomes Pharmaceutical Industry Leader to its Board of Directors

---

Tokyo, March 31<sup>st</sup>, 2020

Noile-Immune Biotech, Inc. announces today the appointment of Philippe Fauchet, OBE, as an external director for its Board of Directors.

Philippe has spent 35 years in the pharmaceutical industry, 20 of which he has spent in Japan, most recently as the Chairman of GlaxoSmithKline K.K. from 2017 to February 2019. Philippe joined GlaxoSmithKline K.K. as President & Representative Director in 2010, having previously been a Senior Vice President, Corporate Business Development Head of Sanofi-Aventis Group. He had been a member of the Management Committee of Sanofi-Aventis Group from 2005.

Alongside various instrumental roles in the pharmaceutical industry, Philippe has been Vice Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan until 2018. He has regularly been elected to the board of the British Chamber of Commerce in Japan (BCCJ) from 2015 to 2019, and is also appointed French Foreign Trade Honorary Advisor (CCE). He is also Adjunct Professor at the University of Tokyo, Graduate School of Medicine, Global Health Policy Department. Philippe was awarded Honorary Officer of the Most Excellent Order of the British Empire (OBE) in 2014.

Noile-Immune will be significantly benefited by Philippe's extended experience in the pharmaceutical industry including his recent role as the chairman of GlaxoSmithKline K.K. His expertise will be an asset on strategic business deliverables and stable management foundation.

In order to ensure sustainable corporate growth, Noile-Immune is enhancing its corporate governance and strengthening its internal controls. Noile-Immune will also continue to further expand business development of innovative cancer immunotherapy for cancer patients,